Retrospective Study
Copyright ©The Author(s) 2021.
World J Crit Care Med. Jan 9, 2021; 10(1): 12-21
Published online Jan 9, 2021. doi: 10.5492/wjccm.v10.i1.12
Table 1 Description of the studied group
VariablenMinimumMaximummean ± SD
Age399187951.9 ± 11.3
BMI (kg/m2)39918.843.725.1 ± 7.1
Creatinine (μmol/L)39754.9378.199.8 ± 55.8
EF%388186545.8 ± 8.9
Additive Euro score3980194.6 ± 3.1
CPB time (min)3930377118.1 ± 46.9
ACC time (min)392018886.1 ± 38.7
Anesthesia time (min)398220630295.7 ± 71.2
VIS3980296 ± 2.1
LOSICU (h)3972632065.9 ± 46.1
LOV (min)39719017300432 ± 65
LOShosp (d)394624528.1 ± 12.9
Table 2 Demographic differences between both groups
VariableGroup I (LMS), 75 (%)Group II (no LMS), 324 (%)P value
Age58.3 ± 11.855.19 ± 9.70.06
Gender (male)62 (82.6)264 (81.4)0.34
Diabetes39 (52)144 (44.4)0.05
Hypertension32 (42.6)144 (44.4)0.13
Euro score5.8 ± 3.95.0 ± 3.60.6
BMI30.1 ± 6.327.9 ± 5.80.6
EF < 4024 (32)86 (26.5)0.07
IABP28 (37.3)80 (24.6)0.05
Elective surgery45 (60)224 (66.6)0.5
Basal creatinine (μmol/L)98.7 ± 46.594.7 ± 43.10.6
Table 3 Main differences in both studied groups
VariableGroup I (LMS), 75 (%)Group II (no LMS), 324 (%)P value
Inotrops
Dopamine, mean dose (μg/kg/min), mean ± SD9 (12), 6.50 ± 3.1031 (9.6), 7.23 ± 15.20.5, 0.34
Adrenaline, mean dose (μg/kg/min), mean ± SD6 (8), 0.06 ± 0.0127 (8.3), 0.05 ± 0.0090.6, 0.8
Noradrenline, mean dose (μg/kg/min), mean ± SD12 (16), 0.08 ± 0.0143 (13.2), 0.07 ± 0.0080.4, 0.7
Dobutamine, mean dose (μg/kg/min), mean ± SD4 (5.3), 4.5 ± 1.411 (3.3), 3.9 ± 1.10.06, 0.09
Milrinone, mean dose (μg/kg/min), mean ± SD3 (4), 0.56 ± 0.057 (2.1), 0.6 ± 0.040.9, 0.4
Intraoperative parameters
CPB time (min)139 ± 43125 ± 69.60.6
ACC time (min)87.1 ± 3479.3 ± 30.10.9
Anesthesia time (min)6.6 ± 1.46.5 ± 1.80.9
Grafts3.1 ± 0.83.4 ± 1.010.7
Postoperative parameters
LOV (min)384.1 ± 123375.1 ± 1190.8
LOSICU (h)65.9 ± 46.163.4 ± 43.90.6
LOShosp (d)16.1 ± 4.214.7 ± 3.70.6
VIS6.4 ± 2.66.1 ± 2.20.4
Post-operative outcome
POAF12 (16)39 (12)0.06
AKI20 (26.7)75 (23.1)0.09
In-hospital-mortality2 (2.7)7 (2.1)0.8
VAP1 (1.3)5 (1.5)0.7
VA-ECMO2 (2.7)4 (1.2)0.08
Re-admission ICU2 (2.7)8 (2.5)0.8
Re-exploration6 (8)26 (8.6)0.5
PMI3 (4)11 (3.3)0.4